MesaGreen Announces Progress
K9MGP Seizure Program In July 2019, MesaGreen Pharmaceutical (MGP) entered into a research agreement with the University of Minnesota Schools…
K9MGP Seizure Program In July 2019, MesaGreen Pharmaceutical (MGP) entered into a research agreement with the University of Minnesota Schools…
Mesa Science Associates is pleased to announce that Peyton Coady, a former intern at MSA will be graduating from James…
Our surviving the Covid-19 experience has been an example of what having a great team can do for a company….
Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely. Unfortunately,…
The third in a series of studies measured cerebrospinal fluid epinephrine pharmacokinetics, nasal mucosa effects, plasma epinephrine pharmacokinetics, and cardiovascular…
May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…
The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….
April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…
March 16, 2020 MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating…
February 17, 2020 Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system…